Shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.00 and traded as high as $0.0001. Nabriva Therapeutics shares last traded at $0.00, with a volume of 0 shares traded.
Nabriva Therapeutics Stock Performance
The company has a market cap of $45.46 million, a P/E ratio of 0.00 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc is a clinical‐stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel anti‐infective agents. The company’s research efforts focus on addressing critical unmet needs in the treatment of serious bacterial infections, with a particular emphasis on combating antimicrobial resistance. Since its founding in 2006, Nabriva has built a portfolio of antibiotic candidates designed to offer new therapeutic options for patients suffering from community‐acquired and hospital‐acquired infections.
The company’s lead product, lefamulin, is a first‐in‐class pleuromutilin antibiotic that received U.S.
Read More
- Five stocks we like better than Nabriva Therapeutics
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Wall Street Alert: Buy AES
- NEW LAW: Congress Approves Setup For Digital Dollar?
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
